Company Overview of Hetero Drugs Limited
Hetero Drugs Limited, a pharmaceutical company, develops, manufactures, and markets active pharmaceutical ingredients (APIs), intermediate chemicals, and generic finished dosages in India. The company offers APIs in the areas of antiretroviral and oncology products to the global pharmaceutical market; finished dosages in various therapeutic areas, including antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, anti-diabetics, pain management, anti-infectives, dermatology, and oncology; and oncology products, including injectables, solid/liquid oral dosages, ointments, soft gelatine capsules, and inhalers. It also develops and manufactures bio-generics; and provid...
HETERO CORPORATE INDUSTRIAL ESTATES
Founded in 1993
Key Executives for Hetero Drugs Limited
Founder, Chairman and Managing Director
Director of Production and Whole Time Director
Compensation as of Fiscal Year 2016.
Hetero Drugs Limited Key Developments
Hetero Bags DCG(I) Approval for Generic Version of Daclatasvir Tablets
Dec 14 15
Hetero has received the approval from Drug Controller General (India) for the generic version of Daclatasvir tablets (30mg, 60mg). The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India. The product is a generic version of Bristol-Myers Squibb's brand 'Daklinza,' approved by US FDA in July 2015. Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment. Research studies indicates that this drug enables the rapid decline of Hepatitis C virus. Daclatasvir is included the World Health Organization's List of Essential medicines.
Cipla Reportedly Mulls Acquisition Of Hetero’s US Business
Sep 3 15
Cipla Limited (NSEI:CIPLA) is in talks to acquire US business of Hetero Drugs Limited, which is run under the Camber Pharmaceuticals brand, according to sources. The deal, which may be announced in the next few days, values Hetero's US business at $500-550 million and may including manufacturing facilities, sources added. When contacted by CNBC-TV18, Cipla said that it did not want to comment on any product or partner discussions and that it was "constantly in discussions with multiple partners on potential collaborations". "Our aspiration is to drive access to and ensure availability of affordable medicines," Cipla said.
Hetero Announces the Launch of Biosimilar Rituximab MABALL in India
Aug 5 15
Hetero Group announced the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India. The launch of biosimilar Rituximab will provide a much needed access to patients in India suffering with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL). Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths - 100mg/10ml and 500mg/50ml.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|